MRA/ACS Special Opportunity
MRA/ACS Joint Funding Opportunity: Understanding and Managing Metastasis
The Melanoma Research Alliance (MRA) is pleased to announce a special funding opportunity jointly supported by MRA and the American Cancer Society (ACS), Understanding and Managing Metastasis in Melanoma and Other Cancers.
MRA and ACS have each committed $1 million for the grant awards. The combined $2 million will be used to fund two team awards with terms of up to 3 years, at $1 million each. Proposals must include at least a 50% focus on melanoma research but need not be limited to this disease area.
A request for applications (RFA) is now available to researchers at academic institutions in the United States. More information about the RFA and relevant deadlines can be found here.
Please note the following key deadlines:
- January 16, 2019: Letters of Intent due
- April 15, 2019: Full application due.
- January 1, 2020: Grant term begins.
All proposals are due by 5:00 pm Eastern Time. Proposals should be submitted via the proposalCENTRAL on-line application tool: https://proposalcentral.altum.com/. We strongly encourage you to share this RFP with your colleagues who might want to apply for funding. Please also inform us of others who might not be on our email list who should receive this announcement.
Tasheema Prince, MRA Scientific Program Manager
Melanoma is a leading cause of new cancers, and more effective options for patients and those at risk are urgently needed. Recent scientific and clinical advances have provided new hope, but much work remains to be done to end suffering and death from melanoma.